High PMS2 Expression-Based Nomogram for Risk Stratification in Resected Hepatocellular Carcinoma: Application to Recurrence and Neoadjuvant Therapy Selection

Journal of Cancer · Published 2026-03-25 · DOI 10.7150/jca.131997

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.7150/jca.131997

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy · Journal of Cancer · 2026 · Same journal
• Circulating Tumor Cells Detected Using EpAb3-5 as Prognostic Indicators in Head and Neck Squamous Cell Carcinoma · Journal of Cancer · 2026 · Same journal
• RNF216 as a Promising Biomarker for Prognosis, Immunotherapy, and Chemotherapy in LIHC: A Comprehensive Pan-Cancer Analysis and Experimental Validation · Journal of Cancer · 2026 · Same journal
• A Comprehensive Review of Nanotechnological Innovations in Cancer: from Molecular Pathways to Clinical Applications · Journal of Cancer · 2026 · Same journal
• Exosomes in Cancer Biology: Emerging Biomarkers and Therapeutic Targets · Journal of Cancer · 2026 · Same journal
• Potential influence of omentin-1 genetic variants on the clinicopathological features of patients with hepatocellular carcinoma · Journal of Cancer · 2026 · Same journal
• Association of NAP1L1 polymorphism with clinicopathological progression in oral squamous cell carcinoma · Journal of Cancer · 2026 · Same journal
• Assessing the Association Between Genetic Variants in ACE, SOD1, and PER3 and their Role in Breast Cancer Risk among Jordanian Women · Journal of Cancer · 2026 · Same journal
• Inflammation Drives Phosphorylation and Acetylation of MutS Homolog 3 and Interaction with Cytosolic HDAC6 · Journal of Cancer · 2026 · Same journal
• Proteasome Assembly Chaperone 3 Defines Metabolic-Immune Programs and Poor Prognosis in Breast Cancer via Multi-Omics Approaches · Journal of Cancer · 2026 · Same journal